Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
Condition(s):Lymphoma, Mantle-CellLast Updated:March 23, 2021Recruiting
Hide Studies Not Open or Pending
Condition(s):Lymphoma, Mantle-CellLast Updated:March 23, 2021Recruiting
Condition(s):Mantle Cell LymphomaLast Updated:March 18, 2021Recruiting
Condition(s):Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell LymphomaLast Updated:February 5, 2020Recruiting
Condition(s):Mantle Cell Lymphoma; LymphomaLast Updated:December 6, 2012Withdrawn
Condition(s):Lymphoma, Mantle- CellLast Updated:October 22, 2020Completed
Condition(s):Mantle Cell LymphomaLast Updated:March 18, 2020Recruiting
Condition(s):Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-CellLast Updated:February 10, 2021Recruiting
Condition(s):Mantle Cell LymphomaLast Updated:April 24, 2014Completed
Condition(s):Mantle Cell LymphomaLast Updated:March 22, 2021Recruiting
Condition(s):Lymphoma, Mantle-cellLast Updated:January 24, 2017Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.